国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

Intracranial Mesenchymal Chondrosarcoma: Report of 16 Cases

第一作者:Wang Ke, Ke

通讯作者:Wu Zhen, Zhen

Chemotherap Intracranial mesenchymal chondrosarcom

基本信息

  • 负责人:Wang Ke, Ke
  • 数据来源: OTHERS
  • 论文编号:OTHERS20190734
  • 发表时间:2018-05-01

2018-05-01

已发表文章

发表杂志:World Neurosurgery

发表类型: Article

影响因子(IF): 2.104

PMID: 29783007 Pubmed原文链接 全文下载

主要研究背景及目的

方法

Clinical data for 16 patients with MCS were reviewed retrospectively to evaluate their clinical characteristics, management, and outcomes.

结论

Clinical characteristics of MCS are variable. The current management of intracranial MCS referring to conventional chondrosarcoma could not yield satisfactory outcomes. Further study is needed to identify the optimal treatments.

主要结果

This study included 11 male and 5 female patients with a mean age of 22.9 ± 14.4 years. The most common presentations were headache (n = 10; 62.5%), followed by cranial deficits (n = 7; 43.6%). The radiologic spectrum for MCS was broad, and only 18.8% (3/16) of MCSs were correctly diagnosed preoperatively. Aggressive resection (including subtotal resection and gross total resection) and partial resection was performed in 62.5% (10/16) and 37.50% (6/16) of patients. With a median follow-up of 34 months (range, 10-78 months), 5 patients (31.3%) died and 8 patients (50%) developed tumor recurrence. The 1-, 3-, and 5-year rates of progression-free survival and overall survival were 86%, 53%, and 42% and 93%, 70%, and 56%, respectively. Although the differences were not significantly different, aggressive resection and the use of radiotherapy tended to improve the prognosis of the patients.